• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505.

作者信息

Evans Douglas B

出版信息

Ann Surg. 2020 Sep 1;272(3):487. doi: 10.1097/SLA.0000000000004131.

DOI:10.1097/SLA.0000000000004131
PMID:32657915
Abstract
摘要

相似文献

1
The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505.可切除胰腺癌新辅助治疗的复杂性：从SWOG S1505研究中获得的经验教训
Ann Surg. 2020 Sep 1;272(3):487. doi: 10.1097/SLA.0000000000004131.
2
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.SWOG S1505 研究的手术结果：吉西他滨/白蛋白紫杉醇对比改良 FOLFIRINOX 用于可切除胰腺导管腺癌围手术期治疗的随机临床试验。
Ann Surg. 2020 Sep 1;272(3):481-486. doi: 10.1097/SLA.0000000000004155.
3
Neoadjuvant -paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX.新辅助紫杉醇和吉西他滨用于无法接受FOLFIRINOX方案治疗的可切除边缘或局部晚期不可切除胰腺腺癌患者。
Anticancer Res. 2018 Jul;38(7):4035-4039. doi: 10.21873/anticanres.12692.
4
ASO Author Reflections: Neoadjuvant Treatment of Resectable and Borderline-Resectable Pancreatic Head Adenocarcinoma: Is FOLFIRINOX Better than Gem/Nab-Paclitaxel?ASO作者反思：可切除及边界可切除胰头腺癌的新辅助治疗：FOLFIRINOX方案是否优于吉西他滨/纳米白蛋白结合型紫杉醇？
Ann Surg Oncol. 2018 Dec;25(Suppl 3):808-809. doi: 10.1245/s10434-018-6833-7. Epub 2018 Oct 8.
5
ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes.ASO作者反思：吉西他滨联合白蛋白结合型紫杉醇新辅助化疗对可切除边缘性胰腺癌手术结局的影响
Ann Surg Oncol. 2019 Dec;26(Suppl 3):739-740. doi: 10.1245/s10434-019-07857-z. Epub 2019 Sep 19.
6
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.白蛋白结合型紫杉醇联合吉西他滨对比白蛋白结合型紫杉醇联合吉西他滨序贯 FOLFIRINOX 诱导化疗治疗局部晚期胰腺癌（NEOLAP-AIO-PAK-0113）：一项多中心、随机、Ⅱ期临床试验。
Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138. doi: 10.1016/S2468-1253(20)30330-7. Epub 2020 Dec 16.
7
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015).随机 II 期研究：吉西他滨和 S-1 联合治疗与吉西他滨和白蛋白结合型紫杉醇纳米粒联合治疗用于可切除/交界可切除胰腺导管腺癌（PDAC-GS/GA-rP2，CSGO-HBP-015）新辅助化疗。
Trials. 2021 Aug 26;22(1):568. doi: 10.1186/s13063-021-05541-w.
8
A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma.吉西他滨联合纳米白蛋白紫杉醇新辅助治疗与先行手术治疗胰腺腺癌的对比研究
Surg Oncol. 2017 Dec;26(4):402-410. doi: 10.1016/j.suronc.2017.08.003. Epub 2017 Aug 24.
9
Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.吉西他滨联合纳米白蛋白紫杉醇术前治疗是一种安全有效的胰腺腺癌化疗方法。
Eur J Surg Oncol. 2016 Sep;42(9):1394-400. doi: 10.1016/j.ejso.2016.01.006. Epub 2016 Jan 29.
10
Application of Nab-paclitaxel combined with gemcitabine in neoadjuvant chemotherapy laparoscopic followed by pancreatoduodenectomy to a patient with pancreas head cancer invading to protal vein.纳米白蛋白结合型紫杉醇联合吉西他滨在新辅助化疗腹腔镜术后行胰十二指肠切除术治疗侵犯门静脉的胰头癌患者中的应用
Asian J Surg. 2022 Nov;45(11):2457-2459. doi: 10.1016/j.asjsur.2022.05.099. Epub 2022 Jun 10.

引用本文的文献

1
Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.新辅助治疗与手术优先治疗可切除或交界可切除胰腺癌的比较：一项随机对照试验的系统评价和网络荟萃分析。
PLoS One. 2024 Mar 7;19(3):e0295983. doi: 10.1371/journal.pone.0295983. eCollection 2024.
2
Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2).交界性和局部进展期胰腺癌的切除率和意向治疗结果：一项基于人群、前瞻性队列研究（NORPACT-2）的真实世界数据。
BJS Open. 2023 Nov 1;7(6). doi: 10.1093/bjsopen/zrad137.
3
Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study.
描述胰腺导管腺癌新辅助治疗期间的患者体验：一项定性研究。
World J Gastrointest Oncol. 2022 Jun 15;14(6):1175-1186. doi: 10.4251/wjgo.v14.i6.1175.
4
Present status and perspective of perioperative chemotherapy for patients with resectable pancreatic cancer in Japan.日本可切除胰腺癌患者围手术期化疗的现状与展望
Glob Health Med. 2022 Feb 28;4(1):14-20. doi: 10.35772/ghm.2021.01015.
5
Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma.多专科医生对使用新辅助治疗胰腺导管腺癌的障碍和促进因素的看法。
HPB (Oxford). 2022 Jun;24(6):833-840. doi: 10.1016/j.hpb.2021.10.010. Epub 2021 Oct 25.
6
Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma.护理碎片化对接受新辅助和辅助治疗胰腺腺癌患者结局的影响。
J Surg Oncol. 2022 Feb;125(2):185-193. doi: 10.1002/jso.26706. Epub 2021 Oct 2.